The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Boehringer Ingelheim Rcv Boehringer Ingelheim competitive analysis

Loading summary...

Latest oppositions filed by Boehringer Ingelheim Rcv Boehringer Ingelheim

Explore patent oppositions filed by Boehringer Ingelheim Rcv Boehringer Ingelheim against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3342786
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAMar 22, 2022
EP3177645
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 16, 2021
EP2820151
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation StatusIRMDec 15, 2020
EP2847223
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The SameTRUSTEES OF DARTMOUTH COLLEGEDec 20, 2019
EP2647707
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019
EP2530091
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAJan 2, 2019
EP2567709
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)NOVARTISSep 25, 2018

Latest PTAB cases involving Boehringer Ingelheim Rcv Boehringer Ingelheim

Discover the latest PTAB cases involving Boehringer Ingelheim Rcv Boehringer Ingelheim, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim Rcv Boehringer Ingelheim with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIM7 - - -
CHUGAI SEIYAKU KABUSHIKI KAISHA378 - 1
NOVARTIS6422 - 21
THE UNIVERSITY OF TOKYO - 16 - 1